Shares of AbbVie Inc. rose 3.38% to $192.34 Monday, on what proved to be an all-around great trading session for the stock ...

Shares of AbbVie Inc. ABBV advanced 1.88% to $180.37 Thursday, on what proved to be an all-around favorable trading session ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Roopal Thakkar; Executive Vice President, Research & Development, Chief Scientific Officer; AbbVie Inc Scott Reents ...

AbbVie Inc.’s (NYSE:ABBV) year is off to a very strong start. The company beat Q1 2025 revenue and EPS estimates and raised the full-year EPS guidance range by $0.10 and the full-year revenue ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.80%, which has investors questioning if this is right time ...

AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Roopal Thakkar; Executive Vice President, Research & Development, Chief Scientific Officer; AbbVie Inc Scott Reents; ...

Despite the policy risks, AbbVie delivered a strong first quarter, posting adjusted earnings per share of $2.46, $0.10 above ...

The healthcare industry, an essential component of global well-being and economic resilience, is undergoing significant ...